VIB/VUB spin-off Confo Therapeutics has appointed Dr. Christel Menet as its new Chief Scientific Officer. Menet previously held the position of Director of Chemistry at biotech heavyweight Galapagos, where she was responsible for the full development of the company’s most advanced and successful molecule filgotinib. The JAK1 inhibitor, which has proven to be effective in both Crohn’s disease and rheumatoid arthritis, is currently preparing for phase III clinical trials.
“I am thrilled to join Confo Therapeutics at an exciting time, and am impressed by the broad applicability of the break-through CONFO® technology. It allows medically relevant GPCRs to be stabilized in their active signaling state, revealing new binding pockets accessible for drug discovery. I’m looking forward to contribute to the selection and direction of Confo Therapeutics’ pipeline candidates”, said Dr. Christel Menet.
GPCRs are attractive drug targets since they are involved in many essential cellular processes and diseases. By stabilizing the receptors with the CONFO® technology, GPCR that are currently considered undruggable can be targeted. This opens up treatment possibilities for diseases with high unmet medical needs.
More information at www.confotherapeutics.com
